Britain and America have established a significant bilateral deal that will maintain no import taxes on UK medicine shipments being sold in the American market.
The Terms of the Deal
As part of the deal, the UK has agreed to increase expenditure on medicines through the public health system. This commitment ensures that duties on these key goods will be held at zero for a duration of 36 months.
This agreement comes after recent statements to dramatically increase duties on branded drug products, with potential rates discussed as high as double the cost.
"This arrangement between the UK bolsters the international landscape for new treatments and establishes long-overdue balance to transatlantic medicine commerce," an announcement declared.
Commercial Significance
Pharmaceuticals constitute one of the the United Kingdom's most significant goods shipped to the US, which is by far the largest destination for major companies like GSK and AstraZeneca.
Statistics indicate that in the year to the end of last September, the UK sold pharmaceutical products worth over eleven billion pounds to the US. This amount accounted for nearly one-fifth of all goods exports in that timeframe.
"This guarantee secures employment, boosts funding and facilitates the UK to establish itself as a international leader for medical research," the Business and Trade Secretary remarked.
Key NHS Changes
The deal involves several key changes from the British government:
- Revised Affordability Limit: The UK will raise the affordability limit at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to double total public funding on medicines from 0.3% of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The sum drug companies must pay back to the NHS to stay within budget will be limited at 15%. Previously, repayments topped twenty percent.
Industry Background
The pact comes amid a protracted tension between the pharmaceutical industry and the ministers over spending levels and regulatory access.
This friction were heightened by assertions that US customers were paying several times more for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several large drug company projects in the UK have been paused or cancelled, while multi-billion-dollar investments have been announced toward American operations.
One official acknowledged that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a proportion of its total funding over the last ten years.
